5 Key Takeaways
-
1
Recent breakthroughs in neuroprotective strategies for Parkinson's and Alzheimer's are influencing glaucoma research.
-
2
Dr. Eugene de Juan, Jr. will keynote Glaucoma 360, focusing on the need for neuroprotection in glaucoma.
-
3
De Juan's research at Perceive Pharma aims to develop neuroprotective therapeutics targeting the DLK/LZK pathway.
-
4
PBI-671, a drug developed by Perceive Pharma, shows promise in protecting retinal ganglion cells in animal studies.
-
5
The field of neuroprotection is gaining momentum, with multiple companies exploring treatments for glaucoma and other conditions.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
